Study to Evaluate the Safety, Tolerability, and PK of Fulvestrant After IM Administration
Clinical trial NCT03324061 · COMPLETED
Trial details
- NCT number
- NCT03324061
- Sponsor
- Eagle Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-11-30
- Primary completion
- 2018-07-12
- Enrollment
- 600
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.